Related Experiment Videos
Interventional management of acute myocardial infarction (AMI)
1Department of Cardiology, Prince Charles Hospital, Brisbane, Qld.
Insights
Rapidly restoring blood flow to the heart muscle is key for heart attack survival. Percutaneous coronary intervention (PCI) may be superior to thrombolytic therapy in preventing further heart damage and death.
Area of Science:
- Cardiology
- Emergency Medicine
- Interventional Cardiology
Background:
- Early restoration of blood flow to the myocardium is critical for limiting infarct size and improving survival in acute myocardial infarction (MI).
- Thrombolytic therapy and aspirin have demonstrated efficacy, with accelerated recombinant tissue plasminogen activator being more effective than streptokinase.
- Older patients face higher risks of hemorrhagic stroke with thrombolytics, but MI mortality is also higher, making treatment life-saving.
Purpose of the Study:
- To compare the efficacy of thrombolytic therapy with immediate percutaneous coronary angioplasty (PTCA) in patients with acute myocardial infarction.
- To evaluate outcomes including recurrent ischemia, death, reinfarction, and intracranial hemorrhage.
- To assess the cost-effectiveness and indications for PTCA versus thrombolysis.
Main Methods:
- Review and comparison of clinical trial data for thrombolytic therapy (including accelerated recombinant tissue plasminogen activator and streptokinase) and immediate/direct PTCA.
- Analysis of patient outcomes, focusing on infarct size, survival rates, recurrent ischemia, reinfarction, and intracranial hemorrhage.
- Consideration of patient subgroups, including older patients, those with cardiogenic shock, and contraindications to thrombolysis.
Main Results:
- Thrombolytic therapy fails to restore adequate blood flow in approximately 20% of patients.
- Prompt PTCA is superior to thrombolysis in preventing recurrent ischemia, death, or non-fatal reinfarction, and is associated with a lower risk of intracranial hemorrhage.
- PTCA may be more cost-effective due to shorter hospital stays and reduced need for late revascularization.
Conclusions:
- Immediate PTCA should be considered for patients with acute MI, especially those with cardiogenic shock or contraindications to thrombolytic therapy.
- Excessive delays in hospital arrival and treatment initiation (door-to-needle time) reduce the benefits of prompt reperfusion therapies.
- Coronary angiography and PTCA after fibrinolysis are indicated for patients experiencing spontaneous or exercise-induced ischemia.
Abstract:
The best way to limit infarct size and improve survival in patients with early heart attacks is to restore as quickly as possible patency in the infarct-related artery and blood flow to the threatened myocardium. The value of thrombolytic therapy and aspirin has been shown in large clinical trials. A regimen of accelerated recombinant tissue plasminogen activator is more effective than those using streptokinase. In older patients, there is a greater risk of haemorrhagic stroke; nevertheless, thrombolytic treatment saves more lives because the mortality of myocardial infarction (MI) is higher. Thrombolytic therapy fails to restore blood flow sufficiently rapidly or completely in nearly one-fifth of patients. Its efficacy, therefore, has been compared with immediate or direct angioplasty (PTCA). If it can be done promptly enough, PTCA is superior in preventing recurrent ischaemia and the combined outcome of death or non-fatal reinfarction, and is associated with a lesser risk of intracranial haemorrhage. It may also be cheaper because patients spend less time in hospital and fewer of them require late revascularisation. PTCA should be considered for patients with cardiogenic shock or for those in whom there is a contraindication to thrombolytic therapy. The benefits of prompt treatment have been reduced by excessive delay in reaching hospital and door-to-needle time. After fibrinolysis, coronary angiography and PTCA may be reserved for those with spontaneous angina or exercise-induced ischaemia.